ArticleMolecular imaging and biology2011
Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.
Article in Molecular imaging and biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pooled it
- PET findings of intramedullary tumors of the spinal cord using [18F] FDG and [11C] methionine.AJNR. American journal of neuroradiologyTrial
- Utility of various positron emission tomography tracers in differentiating primary central nervous system lymphoma from glioblastoma multiforme.EJNMMI reports · 2026Article
- The Role of 11C-Methionine PET Imaging for the Evaluation of Lymphomas: A Systematic Review.Hematology reports · 2024Review
- Article
- Comparative evaluation ofJournal of neuro-oncology · 2024Article
- Spontaneous Regression of Glioma-Mimicking Brainstem Lesion in a Child: A Case Report.Brain tumor research and treatment · 2024Article
- Neuroradiology of acute pathologies in adults with hematologic malignancies: a pictorial review.Quantitative imaging in medicine and surgery · 2023Review
- Review
- CXCR4-Directed PET/CT with [Molecular imaging and biology · 2022Article
- Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma-a narrative review.Annals of lymphoma · 2021Article
- Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.Clinical nuclear medicine · 2021Article
- Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma.CNS oncology · 2019Article
- 18F-FDG PET/CT in primary brain lymphoma.Journal of neuro-oncology · 2018Article
- Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.BioMed research international · 2018Review
- [Theranostics · 2018Article
- Treatment of primary CNS lymphoma.Current treatment options in neurology · 2014Article
- 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.BioMed research international · 2013Review
- Managing lymphoma with non-FDG radiotracers: current clinical and preclinical applications.BioMed research international · 2013Review
- Insufficiency of positron emission tomography and magnetic resonance spectroscopy in the diagnosis of intravascular lymphoma of the central nervous system.Case reports in oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) positron emission tomography (PET) has been used as a promising tool to diagnose primary central nervous system (CNS) lymphoma because the tumor shows very high FDG accumulation. Although (11)C-methionine (MET) PET has been reported to be useful for evaluating various brain tumors, the role of MET PET in CNS lymphoma is unclear. We compared the uptake of MET and FDG in patients with CNS lymphoma. PROCEDURES: Thirteen immunocompetent patients with CNS lymphoma were examined. All patients underwent PET with MET (15 min p.i.) and FDG (60 min p.i.). PET results were evaluated by visual and semi-quantitative analysis. For semi-quantitative analysis, the standardized uptake value (SUV) and tumor to contralateral normal brain tissue (T/N) ratio were determined by region-of-interest analysis.
resultsFor detection of CNS lymphoma, sensitivity of PET using both MET and FDG was 100%. The mean (±SD) value of SUV in the contralateral normal brain tissue using MET (1.43 ± 0.21) was significantly lower than that using FDG (5.58 ± 1.79; p < 0.002). The mean (±SD) value of SUV in the CNS lymphoma using MET (4.27 ± 1.91) was significantly lower than that of FDG (13.94 ± 5.65; p < 0.002). There were no significant differences between mean (±SD) T/N ratios using MET PET (3.00 ± 1.26) and FDG PET (2.74 ± 1.25).
conclusionThere was no significant difference between T/N ratios using MET PET and FDG PET, although uptake of MET in CNS lymphoma was significantly lower than that of FDG. MET PET showed as high a sensitivity as FDG PET for the detection of primary lesions in patients with CNS lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.